Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

Caryn Lerman; E. Paul Wileyto; Janet Audrain; Angela Pinto; Susan Kucharski; Ray Niaura; Peter G. Shields; Larry H. Hawk; Shiva Krishnan; Leonard H. Epstein

doi:10.1037/0278-6133.22.5.541

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

Caryn Lerman, E. Paul Wileyto, Janet Audrain, Angela Pinto, Susan Kucharski, Ray Niaura, Peter G. Shields, Larry H. Hawk, Shiva Krishnan, Leonard H. Epstein

Global Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N = 418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 X SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.

Original language	English (US)
Pages (from-to)	541-548
Number of pages	8
Journal	Health Psychology
Volume	22
Issue number	5
DOIs	https://doi.org/10.1037/0278-6133.22.5.541
State	Published - Sep 2003

Keywords

Bupropion
Dopamine
Genetics
Smoking
Tobacco
Treatment

ASJC Scopus subject areas

Applied Psychology
Psychiatry and Mental health

Access to Document

10.1037/0278-6133.22.5.541

Cite this

@article{adb1ca83fe1e45f69334ed342456329f,

title = "Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial",

abstract = "This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N = 418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 X SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.",

keywords = "Bupropion, Dopamine, Genetics, Smoking, Tobacco, Treatment",

author = "Caryn Lerman and Wileyto, {E. Paul} and Janet Audrain and Angela Pinto and Susan Kucharski and Ray Niaura and Shields, {Peter G.} and Hawk, {Larry H.} and Shiva Krishnan and Epstein, {Leonard H.}",

year = "2003",

month = sep,

doi = "10.1037/0278-6133.22.5.541",

language = "English (US)",

volume = "22",

pages = "541--548",

journal = "Health Psychology",

issn = "0278-6133",

publisher = "American Psychological Association",

number = "5",

}

TY - JOUR

T1 - Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

AU - Lerman, Caryn

AU - Wileyto, E. Paul

AU - Audrain, Janet

AU - Pinto, Angela

AU - Kucharski, Susan

AU - Niaura, Ray

AU - Shields, Peter G.

AU - Hawk, Larry H.

AU - Krishnan, Shiva

AU - Epstein, Leonard H.

PY - 2003/9

Y1 - 2003/9

N2 - This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N = 418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 X SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.

AB - This study examined the role of dopaminergic genes in prospective smoking cessation and response to bupropion treatment in a placebo-controlled clinical trial. Smokers of European ancestry (N = 418) provided blood samples for genetic analysis and received either bupropion or placebo (10 weeks) plus counseling. Assessments included the dopamine D2 receptor (DRD2) genotype, dopamine transporter (SLC6A3) genotype, demographic factors, and nicotine dependence. Smoking status was verified at the end of treatment (EOT) and at 6-month follow-up. The results provided evidence for a significant DRD2 X SLC6A3 interaction effect on prolonged smoking abstinence and time to relapse at EOT, independent of treatment condition. Such effects were no longer significant at 6-month follow-up, however. These results provide the first evidence from a prospective clinical trial that genes that alter dopamine function may influence smoking cessation and relapse during the treatment phase.

KW - Bupropion

KW - Dopamine

KW - Genetics

KW - Smoking

KW - Tobacco

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=10744220811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744220811&partnerID=8YFLogxK

U2 - 10.1037/0278-6133.22.5.541

DO - 10.1037/0278-6133.22.5.541

M3 - Article

C2 - 14570538

AN - SCOPUS:10744220811

SN - 0278-6133

VL - 22

SP - 541

EP - 548

JO - Health Psychology

JF - Health Psychology

IS - 5

ER -

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this